Hartford Financial Management’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-240
| Closed | -$7K | – | 380 |
|
|
2022
Q3 | $7K | Buy |
+240
| New | +$9.1K | ﹤0.01% | 293 |
|
|
2022
Q2 | – | Sell |
-240
| Closed | -$13K | – | 388 |
|
|
2022
Q1 | $13K | Sell |
240
-240
| -50% | -$13K | ﹤0.01% | 277 |
|
|
2021
Q4 | $26K | Hold |
480
| – | – | 0.01% | 246 |
|
|
2021
Q3 | $23K | Hold |
480
| – | – | 0.01% | 246 |
|
|
2021
Q2 | $24K | Sell |
480
-160
| -25% | -$7.69K | 0.01% | 243 |
|
|
2021
Q1 | $29K | Hold |
640
| – | – | 0.01% | 231 |
|
|
2020
Q4 | $29K | Hold |
640
| – | – | 0.01% | 229 |
|
|
2020
Q3 | $30K | Hold |
640
| – | – | 0.01% | 219 |
|
|
2020
Q2 | $33K | Hold |
640
| – | – | 0.01% | 213 |
|
|
2020
Q1 | $30K | Sell |
640
-120
| -16% | -$6.4K | 0.01% | 211 |
|
|
2019
Q4 | $45K | Sell |
760
-291
| -28% | -$16.2K | 0.01% | 216 |
|
|
2019
Q3 | $56K | Buy |
1,051
+291
| +38% | +$15K | 0.02% | 205 |
|
|
2019
Q2 | $38K | Hold |
760
| – | – | 0.01% | 228 |
|
|
2019
Q1 | $40K | Hold |
760
| – | – | 0.01% | 224 |
|
|
2018
Q4 | $36K | Hold |
760
| – | – | 0.01% | 233 |
|
|
2018
Q3 | $38K | Hold |
760
| – | – | 0.01% | 244 |
|
|
2018
Q2 | $38K | Hold |
760
| – | – | 0.01% | 244 |
|
|
2018
Q1 | $37K | Hold |
760
| – | – | 0.02% | 186 |
|
|
2017
Q4 | $33K | Hold |
760
| – | – | 0.02% | 196 |
|
|
2017
Q3 | $38K | Hold |
760
| – | – | 0.02% | 203 |
|
|
2017
Q2 | $40K | Buy |
760
+120
| +19% | +$6.4K | 0.02% | 197 |
|
|
2017
Q1 | $33K | Hold |
640
| – | – | 0.02% | 198 |
|
|
2016
Q4 | $31K | Hold |
640
| – | – | 0.02% | 171 |
|
|
2016
Q3 | $34K | Hold |
640
| – | – | 0.02% | 177 |
|
|
2016
Q2 | $34K | Hold |
640
| – | – | 0.02% | 162 |
|
|
2016
Q1 | $32K | Hold |
640
| – | – | 0.02% | 165 |
|
|
2015
Q4 | $32K | Hold |
640
| – | – | 0.02% | 165 |
|
|
2015
Q3 | $30K | Hold |
640
| – | – | 0.02% | 162 |
|
|
2015
Q2 | $33K | Buy |
+640
| New | +$36K | 0.02% | 174 |
|
|
2015
Q1 | – | Sell |
-640
| Closed | -$34K | – | 155 |
|
|
2014
Q4 | $34K | Hold |
640
| – | – | 0.02% | 155 |
|
|
2014
Q3 | $36K | Hold |
640
| – | – | 0.02% | 169 |
|
|
2014
Q2 | $42K | Sell |
640
-88
| -12% | -$5.96K | 0.03% | 162 |
|
|
2014
Q1 | $48K | Hold |
728
| – | – | 0.03% | 149 |
|
|
2013
Q4 | $48K | Hold |
728
| – | – | 0.03% | 151 |
|
|
2013
Q3 | $45K | Sell |
728
-150
| -17% | -$9.66K | 0.03% | 163 |
|
|
2013
Q2 | $55K | Buy |
+878
| New | +$55.7K | 0.04% | 153 |
|
Other funds holding GSK
JEST
AWA
Hartford Financial Management's GSK Position: Q4 2022 in Review
Hartford Financial Management sold out of GSK (GSK) in Q4 2022, closing a stake of 240 shares — an estimated $7K sold.
Hartford Financial Management first reported a position in GSK in Q2 2013 and held it in 36 quarters. The position peaked at $56K in Q3 2019. 813 funds tracked by Wall St. Rank hold GSK as of Q4 2022.
- Hartford Financial Management reported no remaining GSK position as of Q4 2022 after selling out during the quarter.
- Hartford Financial Management sold 240 GSK shares in Q4 2022, an estimated $7K.
- Hartford Financial Management first reported a position in GSK in Q2 2013 and held it in 36 quarters.
- Hartford Financial Management's GSK position peaked at $56K in Q3 2019.
- 813 funds tracked by Wall St. Rank held GSK as of Q4 2022.
Based on Hartford Financial Management's 13F filing for Q4 2022, filed 1 Feb 2023.